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Injury of oligodendrocytes (OLs) induces demyelination, and patients with neurodegenerative diseases exhibit
demyelination concomitantly with neurological deficit and cognitive impairment. Oligodendrocyte progenitor
cells (OPCs) are present in the adult central nervous system (CNS), and they can proliferate, differentiate, and
remyelinate axons after damage. However, remyelination therapies are not in clinical use. Multiple sclerosis (MS)
is a major demyelinating disease in the CNS. Mesenchymal stromal cells (MSCs) have demonstrated therapeutic
promise in animal models and in clinical trials of MS. Exosomes are nanoparticles generated by nearly all cells
and they mediate cell-cell communication by transferring cargo biomaterials. Here, we hypothesize that exo
somes harvested from MSCs have a similar therapeutic effect on enhancement of remyelination as that of MSCs.
In the present study we employed exosomes derived from rhesus monkey MSCs (MSC-Exo). Two mouse models of
demyelination were employed: 1) experimental autoimmune encephalomyelitis (EAE), an animal model of MS;
and 2) cuprizone (CPZ) diet model, a toxic demyelination model. MSC-Exo or PBS were intravenously injected
twice a week for 4 weeks, starting on day 10 post immunization in EAE mice, or once a week for 2 weeks starting
on the day of CPZ diet withdrawal. Neurological and cognitive function were tested, OPC differentiation and
remyelination, neuroinflammation and the potential underlying mechanisms were investigated using immuno
fluorescent staining, transmission electron microscopy and Western blot. Data generated from the EAE model
revealed that MSC-Exo cross the blood brain barrier (BBB) and target neural cells. Compared with the controls (p
< 0.05), treatment with MSC-Exo: 1) significantly improved neurological outcome; 2) significantly increased the
numbers of newly generated OLs (BrdU+/APC+) and mature OLs (APC+), and the level of myelin basic protein
(MBP); 3) decreased amyloid-β precursor protein (APP)+ density; 4) decreased neuroinflammation by increasing
the M2 phenotype and decreasing the M1 phenotype of microglia, as well as their related cytokines; 5) inhibited
the TLR2/IRAK1/NFκB pathway. Furthermore, we confirmed that the MSC-Exo treatment significantly improved
cognitive function, promoted remyelination, increased polarization of M2 phenotype and blocked TLR2 signaling
in the CPZ model. Collectively, MSC-Exo treatment promotes remyelination by both directly acting on OPCs and
indirectly by acting on microglia in the demyelinating CNS. This study provides the cellular and molecular basis
for this cell-free exosome therapy on remyelination and modulation of neuroinflammation in the CNS, with great
potential for treatment of demyelinating and neurodegenerative disorders.

Abbreviations: BBB, blood brain barrier; BrdU, bromodeoxyuridine; CNS, central nervous system; CPZ, cuprizone; EAE, experimental autoimmune encephalo
myelitis; MBP, myelin Basic Protein; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; MSC, mesenchymal stromal cell; OL, oligodendrocyte; OPC,
oligodendrocyte precursor cells.
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1. Introduction

MSCs as a remyelination therapy. Therefore, we propose that a funda
mental biological cell-cell communication unit, exosomes released from
MSCs, likely mediate the therapeutic effects of MSCs on neuro
regeneration and remyelination, and therefore may be used as a
replacement of MSC therapy (Zhang et al., 2019b).
Exosomes are endosomal origin membrane extracellular vesicles
with a size of ~30 to 150 nm released by all living cells and circulate in
body fluids (Barteneva et al., 2013; Pant et al., 2012; Zhang and Chopp,
2016). They are natural biological materials with intrinsic function and
protein machinery that safely and efficiently transfer their cargo bio
materials between source and recipient cells over long distances, and
exosomes play an important role in intercellular communication
(Kourembanas, 2015; Thery et al., 2002). Exosomes are being increas
ingly employed as therapeutic vehicles (Chopp and Zhang, 2015; Thery
et al., 2002; Xin et al., 2014; Zhang and Chopp, 2016). There is robust
literature that exosome therapy appears safe with low immunogenicity
(Alvarez-Erviti et al., 2011; Cully, 2021; Kalani et al., 2014; S et al.,
2013). Our studies have also confirmed the safety, efficacy and apparent
lack of immunogenicity of exosome therapy in multiple xenograft
studies; for example, monkey MSC-Exo therapy was applied to the
traumatic brain injury (TBI) model in swine (Williams et al., 2019);
human MSC-Exo treatment was used in a TBI model in rat (Zhang et al.,
2017a; Zhang et al., 2021; Zhang et al., 2020); human umbilical cord
blood derived exosomes were employed to treat stroke mice with dia
betes mellitus (Venkat et al., 2021).
Since exosomes carry characteristic of the donor cells (Gorabi et al.,
2019), by delivery of biomaterials to the recipient cells, our and other's
studies have demonstrated that exosomes derived from MSCs (MSC-Exo)
enhance neuroregeneration and functional recovery in animal models of
CNS diseases and damage (Gorabi et al., 2019; Phinney and Pittenger,
2017; Reza-Zaldivar et al., 2018; Zhang et al., 2019b), e.g. stroke (Xin
et al., 2017a; Xin et al., 2012; Xin et al., 2013a; Xin et al., 2013b) and TBI
(Zhang et al., 2015b; Zhang et al., 2017a), and promote axonal growth of
cortical neurons in vitro (Zhang et al., 2017c). Compared with cell-based
therapy, exosomes are easily harvested and generated at large-scale
from cells, and pre- and clinical trials indicate that exosome approach
is safe, efficacious and feasible. Since exosomes mediate intercellular
communication, exosomes engineered to contain enriched beneficial
cargos, e.g. microRNA (miRNA), may enhance the therapeutic effects
(Venkat et al., 2018; Xin et al., 2017a).
Studies on the therapeutic effects of MSC-Exo treatment of EAE have
primarily focused on immunomodulatory properties of MSC-Exo, for
example, reduction of neuroinflammation by MSC-Exo results in
reduction of demyelination (Giunti et al., 2021; Li et al., 2019; Riazifar
et al., 2019). However, in the present study, we hypothesized that MSCExo therapy enhances remyelination and thereby ameliorates neuro
logical dysfunction in preclinical models of MS by directly promoting
OPC differentiation and indirectly by modulating neuroinflammation in
the CNS. Two demyelination animal models, the inflammatory demye
lination model (EAE) and the toxic demyelination model (CPZ) were
employed to test the following hypotheses, that MSC-Exo: 1) enter the
CNS and directly target parenchymal cells; 2) improve neurological and
cognitive functional recovery after demyelination; 3) increase OPC dif
ferentiation and remyelination; 4) reduce axonal damage; 5) increase
M1/M2 polarization; 6) reduce neuroinflammation; 7) inhibit Toll-like
receptor 2 (TLR2)/interleukin-1 receptor–associated kinase 1
(IRAK1)/NF-κB signaling pathway.

Oligodendrocytes (OLs) are the myelinating cells in the central ner
vous system (CNS), which form myelin to wrap around and protect
axons to ensure effective transmission of electric pulse (Franklin and
Ffrench-Constant, 2017). OLs are highly vulnerable to CNS insults, such
as ischemia, toxicity, traumatic injury and inflammatory damage by
inflammatory cytokines, reactive oxygen species, and cytotoxic pro
teases (Go et al., 2020; McTigue and Tripathi, 2008). The damaged
myelin leads to demyelination, and demyelinated axons can be further
damaged by inflammatory responses, oxidative stress, mitochondrial
and ion channel dysfunction, and excessive excitatory neurotransmitter,
e.g. glutamate, release which results in functional disability and cogni
tive impairment (Dendrou et al., 2015; Friese et al., 2014; Schattling
et al., 2019). Many neurodegenerative diseases result in demyelination,
for example, multiple sclerosis (MS) and Alzheimer's disease (Nasrabady
et al., 2018; You et al., 2019).
Multiple sclerosis (MS) is an autoimmune disease with progressive
demyelination, and is the most common demyelinating disease in the
CNS (Najm et al., 2015) evoking neurological disability during early
adulthood (Franklin, 2002; Najm et al., 2015; Schattling et al., 2019).
There are ~2.3 million MS patients worldwide. Current treatments of
MS fail to block progression of demyelination and axonal damage, and
reduce neurodegeneration, eventually leading to irreversible functional
deficits (Cole et al., 2017; Najm et al., 2015; Ontaneda et al., 2017;
Schattling et al., 2019). Remyelination is orchestrated by a set of highly
interactive processes. Abundant oligodendrocyte progenitor cells
(OPCs) are present in the adult CNS and they can proliferate, differen
tiate to mature OLs and remyelinate axons; however, this remyelination
response is limited and often insufficient due to intrinsic and extrinsic
obstacles to OPC differentiation and remyelination in the CNS (Desh
mukh et al., 2013; Miron et al., 2013). Currently, there are no effective
remyelination therapies for MS (Najm et al., 2015; Plemel et al., 2017).
Therefore, therapies for MS aimed to enhance OPC differentiation,
remyelination and neuroregeneration are urgently required.
Microglia are the immune cells resident in the CNS, which play
important roles in both damage and repair procedures by secreting cy
tokines, chemokines and growth factors (Adams and Gallo, 2018;
Butovsky and Weiner, 2018; Kremer et al., 2019; Lombardi et al., 2019;
Miron et al., 2013; Wendeln et al., 2018). They are activated and
involved in mediating neurodegenerative disorders, including MS, Alz
heimer's disease, ALS and Parkinson's disease (Lloyd et al., 2019; Rawji
and Yong, 2013). However, microglia also have an important dynamic
role in the repair processes after CNS damage and disorders. Polarization
of the pro-inflammatory microglia to the anti-inflammatory and proregenerative phenotype, promotes neuroregeneration and remyelina
tion (Kremer et al., 2019; Lloyd et al., 2019; Miron et al., 2013).
Therefore, in the present study we investigated whether treatment with
a novel therapeutic agent reduces neuroinflammatory response by pro
moting the polarization of microglia from pro- to anti-inflammatory
functions and thereby facilitates remyelination.
Multipotential mesenchymal stromal cells (MSCs) have been
demonstrated to induce therapeutic benefits in an animal model of MS
and in clinical trials of MS by modulation of immunity and augmenta
tion of intrinsic repair processes (Cohen et al., 2018; Harris et al., 2016;
Karussis et al., 2010; Uccelli et al., 2011; Zhang et al., 2005; Zhang et al.,
2006). We have demonstrated the therapeutic benefits of MSCs in an
animal model of MS, experimental autoimmune encephalomyelitis
(EAE) via their neuroregenerative and immunomodulatory properties
(Zhang et al., 2005). However, cell-based therapies have potential and
unanticipated adverse events in clinical use, for example, accumulation
of exogenously administered cells in many organs after systemic
administration of MSCs raise the risk of emboli generation,
atherosclerosis-like vascular changes and tumor formation, which make
cell-based therapy challenging (Chen et al., 2011; Herberts et al., 2011;
Marks et al., 2017; Wang et al., 2012), and limit clinical application of

2. Material and methods
2.1. Experimental design
The animal protocol in the current study was approved by the Henry
Ford Health System Animal Care and Use Committee. Housing, handling
and experimental procedures were conducted in compliance with all
guidelines and regulations. All efforts were made to minimize animal
2
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suffering, and the number of animals used was the minimum number
required to obtain statistically significant data. Female and male C57BL/
6 mice (6–8 week old) were purchased from Jackson Laboratory. Ani
mals were group housed in 5 per cage in the Bioresources facility with a
12-h light-dark cycle and free access to food and water.

and sustained form of EAE (Aharoni et al., 2008; Constantinescu et al.,
2011). An additional white matter toxicity demyelination model
induced by cuprizone (CPZ) diet was employed. CPZ is a copper chelator
with neurotoxic properties (Gudi et al., 2014). It selectively induces
apoptotic OL death, especially in the corpus callosum. The CPZ model
has well-defined demyelination lesions and relatively few interactions
with the peripheral immune system compared with the EAE model (Cole
et al., 2017; Deshmukh et al., 2013; Zhang et al., 2019a). CPZ was
employed to complement the EAE model to investigate the benefits of
MSC-Exo therapy in demyelinating CNS.

2.2. Preparation, harvesting, and isolation of exosomes from MSCs
MSCs were isolated from the bone marrow of a young adult male
monkey. MSCs were cultured and identified as described in previous
publications (Go et al., 2019; Go et al., 2020). Briefly, MSCs were seeded
into T75 flasks and grown into 2 passages using media containing 20%
FBS and alpha-MEM. 10 × 106 cells were then seeded into a Quantum
incubator (Terumo BCT) and were grown in alpha-MEM with 10%
exosome-depleted FBS (Systems Biosciences, Palo Alto, CA) circulated
through fibronectin coated hollow fibers. Media were harvested starting
on day three, and subsequently, every other day for four days, then every
day for two days, at which time cells were confluent and harvests were
ceased. Exosomes were isolated from the MSC culture media via dif
ferential centrifugation, as described previously (Zhang et al., 2017c).
Briefly, the MSC culture media were centrifuged at 250 xg for 5 min, and
then the supernatants collected and centrifuged at 3000 ×g for 30 min,
followed by filtration through a 0.22 μm filter (SLMP025SS; EMD Mil
lipore Corporation, Billerica, MA) to remove small debris. The resulting
media were further centrifuged at 100,000 ×g for 2 h, 4 ◦ C in a JS-24.38
Swinging Bucket rotor (Beckman Coulter, Fullerton, CA) to sediment
exosomes. The final pellets, were resuspended in phosphate-buffered
saline (PBS) and stored at 4 ◦ C. qNano (Izon, Cambridge, MA, United
States) and transmission electron microscopy TEM (EM208, Philips)
were used to measure exosome particle size; Western blots were used to
identify exosomal marker proteins, CD63 and Alix. An additional group
of exosomes (Exo-con) were generated from fibroblast cells (ATCC, CRL2648) (Wang et al., 2020) following the above methods.

2.5. Induction and treatment of the EAE model and treatments
Female C57BL/6 mice (6– 8 weeks old, Jackson Laboratory) were
employed for the EAE model. Briefly, complete Freund's adjuvant (CFA,
Sigma) was prepared by mixing with Mycobacterium tuberculosis H37Ra
(Difco, Detroit, MI) to make a final concentration containing 4 mg/ml
H37Ra. An emulsion of MOG35-55 (MEVGWYRSPFSRVVHLYRNGK,
GenScript) and CFA was mixed by the same volume. Mice were immu
nized subcutaneously in two sites on either side of the midline on the
lower back, with 200 μg MOG35-55 in 0.2 ml emulsion. Pertussis toxin
(200 ng, List Biological Laboratories, Campbell, CA) was administered
intraperitoneally (i.p.) on the day of MOG35-55 immunization and 48 h
later. EAE mice were divided randomly into 3 groups: MSC-Exo, Exo-con
or PBS treatment groups. Exosomes, including MSC-Exo or Exo-con (5 ×
1010 particles/injection) were administered IV into a tail vein twice a
week for 4 weeks initiated on day 10 post MOG35-55 immunization (p.i.),
respectively. MOG-EAE mice treated with PBS at the same time points as
the MSC-Exo group, were used as a control group. Bromodeoxyuridine
(BrdU, Sigma, 100 mg/kgbw) was injected ip to EAE mice daily for 7
days starting on day 10p.i.. Neurological function test of EAE model.
Mice were scored daily for clinical signs of EAE after MOG35-55 immu
nization and up to day 35 p.i., using a standard EAE scoring system on a
0–5 scale (Shahi et al., 2019; Zhang et al., 2019a) according to the
following increasing severity scale: 0: no disease; 1: loss of tail tone (tail
weakness); 2: hindlimb weakness; 3: hind-limb paralysis; 4: hind-limb
paralysis with forelimb weakness or paralysis; 5: morbidity/death.
Mice with intermediate clinical signs were scored in 0.5 increments.

2.3. Tracking MSC-Exo in the CNS
CD63 is enriched in the exosome membrane and is used as a marker
of exosomes (Johnsen et al., 2014; Marcus and Leonard, 2013; Thuma
and Zoller, 2014). To test whether systemically administered exosomes
can pass the blood brain barrier (BBB), we generated MSC-Exo carrying
CD63-GFP which were isolated from the supernatant of cultured MSCs
transfected with the CD63-GFP plasmid by electroporation (Xin et al.,
2012; Zhang et al., 2017c) using Nucleofector kit (Mirus, MIR50117) kit.
MSC-Exo carrying CD63-GFP (5 × 1010 particles/injection) were intra
venously (IV) injected into normal mice (n = 3). Prior to IV adminis
tration, mice were anesthetized with 1.5% isoflurane in a jar for preinjection anesthetic, and spontaneously respired with 1.5% isoflurane
during IV administration in a 2:1 N2O:O2 mixture using a facemask
connected and regulated with a isoflurane vaporizer (Fraser Harlake).
The isoflurane was scavenged by air vacuum. Four hours after IV
administration, we tracked the MSC-Exo in the CNS. Mice were eutha
nized and transcardially perfused with saline followed by 4% para
formaldehyde. Vibratome sections of brain coronal sections (80 μm
thick) were cut, and fluorescent immunostaining combined with the
antibody against PDGFRa (OPC marker), and Laser scanning confocal
microscopy were used.

2.6. Induction of CPZ demyelination model and treatments
Male C57BL/6 J mice (8 weeks old, Jackson Laboratory) were fed a
diet containing CPZ diet (0.2%, Envigo) for 5 weeks, then returned to
normal diet to allow remyelination for 2 weeks (Zhang et al., 2019a).
Mice were randomly assigned into the MSC-Exo treatment group or the
PBS treatment group (n = 10 per group). Mice were administered MSCExo (5 × 1010 particles/injection) IV or with PBS IV once a week initi
ated on the day of the CPZ diet withdrawal for 2 weeks, to evaluate the
capacity of MSC-Exo to promote cognitive functional recovery and
remyelination. BrdU (100 mg/kgbw) was injected ip to mice daily for 7
days starting on week 4 of CPZ diet. The cognitive function was
measured by the Social behavior test at week 7, at 2 weeks after MSCExo or PBS treatments. The Social behavior test is useful for quanti
fying cognitive deficits including the social interaction and social nov
elty test (Moy et al., 2004; Yadav et al., 2012). Briefly, it was performed
in a three-chambered box made of clear Plexiglas, with 2 doors between
the chambers to control access to the side chambers. In Session I (the
social interaction test), the target mouse was habituated in the middle
chamber for 3 min, and there were 2 wire cups in the other 2 side
chambers, one is empty and one had a never-meet mouse, respectively.
Then the doors to the side chambers were opened, and the target mouse
freely contacted with the empty box or with the mouse (stranger 1) for 3
min. In Session II (the social novelty test), the empty box was changed
and another never-meet mouse (stranger 2) was put in. The target mouse
freely contacted with the mice (strangers 1 and 2) for 3 min. The du
rations of the target mouse contact with the empty box and 2 mice were

2.4. Animal models of demyelination
We employed 2 animal models of demyelination in this study to
investigate the therapeutic effects of MSC-Exo on neurological func
tional recovery, remyelination and modulation of neuroinflammation.
The EAE model is a widely employed animal model of MS, characterized
by inflammation, demyelination and axonal damage in the CNS (Con
stantinescu et al., 2011). Myelin oligodendrocyte glycoprotein peptide
(MOG35-55) was used in this study, which induces a monophasic, chronic
3
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recorded, respectively.

myelin basic protein (MBP, MAB386, Millipore), a marker for myelin
ated mature OLs and myelin; IBA1 (019-19741, Wako), a marker for
microglia; YM1 (AF2446, R&D), a marker for M2 phenotype of micro
glia; iNOS (610431, BD), a marker for M1 phenotype of microglia. The
following antibodies were used as well: IL-1β (ab9787, Abcam), TNFα
(ab9755, Abcam), TGF-β (MAB1835, R&D Sytems), TLR2 (Bioss, bs1019R), phosphate NF-κB (pNF-κB, 3033, cell signaling) and IRAK1
(sc-5288, Santa Cruz Biotechnology). Antibody against β-actin (ab6276,
Abcam) was used as an internal control. Proteins were visualized using a
FluorChem E Imager system (ProteinSimple). The protein band intensity
was quantified based on histogram analysis relative to gel loading in
ternal control β-actin. Measurements were performed in triplicate. Re
sults are presented as fold of control.

2.7. Tissue collection
Mice were sacrificed on day 35 p.i. (EAE model) or week 7 (CPZ
model), respectively, after performance of neurological and cognitive
functional tests. For analysis of immunostaining, animals were eutha
nized and transcardially perfused with saline followed by 4% para
formaldehyde. The lumbar spinal cords were collected from the EAE
model, and the brains were collected from the CPZ model. For trans
mission electron microscopy (TEM) analysis, thoracic spinal cords were
collected from the EAE model. For Western blot analysis, the cervical
and thoracic spinal cords were collected from the EAE model, and corpus
callosum were collected from the CPZ model, and stored at − 80 ◦ C.

2.11. Statistical analyses

2.8. Histological and immunostaining analysis

All of the studies were performed with the experimenter blinded to
treatment groups. Sample size was determined based on our previous
experiments. Each experimental group contained at least n = 10 for
functional tests, n = 6 for morphology and molecular biology studies,
respectively. The EAE model was performed in female mice, because MS
is more prevalent in women (National Multiple Sclerosis Society)
(Compston and Coles, 2002; Harbo et al., 2013); while male mice were
used in the CPZ model, since there are reports to demonstrate that fe
male mice are more resistant to toxic demyelination induced by CPZ
compared to males (Steelman et al., 2012). Data were evaluated for
normality. Since the daily scores of EAE model were not normally
distributed data, we used the non-parametric Kolmogorov-Smirnov test
to test the effect of the MSC-Exo treatment on functional recovery. For
morphology and Western blot analysis, significance between the two
groups was examined using two-way ANOVA analysis. The data are
presented as means ± SE. A value of p < 0.05 is considered significant.

Tissues were post-fixed in paraformaldehyde 24–48 h. After fixation,
lumbar spinal cords and brains were embedded in paraffin and pro
cessed for paraffin sections (6 μm thick). Single immunostaining and
double immunofluorescent staining were employed, using antibodies
against APC (OL marker, GWB-D835F1, Genway), NG2 (OPC cell
marker, AB5230, Millipore), PDGFRa (OPC cell marker, sc-398,206,
Santa Cruz), BrdU (cell proliferation marker, ab1893, Abcam), myelin
basic protein (MBP, myelin marker, Millipore), IBA1 (microglia marker,
019-19741, Wako), YM1 (M2 phenotype of microglia marker, AF2446,
R&D), amyloid-β precursor protein (APP, 2454; Cell Signaling),
respectively. To identify proliferation and differentiation of OPCs,
double-immunostaining of NG2 and APC with BrdU were employed,
respectively. Fields of interest Quantification analysis was focused on: 1)
the corpus callosum (CPZ model) from each brain section; 2) 20 fields of
view from the white matter of lumbar spinal cord (EAE model) were
digitized under a 40× objective (Olympus) using a colour video camera
interfaced with MCID image analysis system (Imaging Research). The
numbers of immunoreactive cells or percentage of immunopositive area
were counted or quantified using a built-in densitometry function in the
MCID image analysis system. Data were averaged to yield either number
of positive cells/mm2 or percentage positive area (%).

3. Results
3.1. Generation and characterization of exosomes derived from MSCs
The characteristics of exosomes were first identified after isolating
exosomes from the supernatant of cultured MSCs in exosome-depleted
growth medium by means of differential ultracentrifugation. The dis
tribution of exosome particle size was determined by qNano. Exosomes
exhibited a size range from 30 to 150 nm with a peak distribution at 100
nm (Fig. 1A). TEM analysis confirmed the size of these exosomes
(Fig. 1B). Western blot analysis showed these exosomes were CD63 and
Alix positive, which are two well characterized exosomal marker pro
teins (Xin et al., 2017b; Zhang et al., 2017c) (Fig. 1C). The harvested
MSC-Exo were resuspended and diluted to 5 × 1010 particles in 200 μl of
PBS, and IV administration of MSC-Exo into animals was performed on
the same day.
We tested whether the MSC-Exo pass the blood brain barrier (BBB),
and are internalized within parenchymal cells in the CNS. MSCs were
first transfected with the CD63-GFP plasmid by electroporation
(Fig. 1D). MSC-Exo were harvested from the supernatant of cultured
MSCs carrying CD63-GFP and then IV injected into mice. As early as 4 h
after IV administration, we found that these exosomes crossed the BBB
as indicated by laser scanning confocal microscopy of immunofluores
cent staining, with green GFP signals present in the CNS and internalized
by parenchymal cells in the CNS (Fig. 1E). Furthermore, using double
immunofluorescent staining combined with the OPC marker, PDGFRa,
we found that MSC-Exo colocalized with OPCs (Fig. 1F).

2.9. Transmission electron microscopy (TEM)
TEM was employed to demonstrate the ultrastructure of myelin and
axons (Zhang et al., 2017b). Briefly, tissues were collected from the
dorsal column of the spinal cord of the EAE mice, cut as 1x1mm3 pieces,
and fixed in 6% glutaraldehyde. The slices were embedded in epoxy
resin. 1.0 μm thick slides cut from epoxy embedded sections were
routinely stained with Paragon to further trim tissue. For post thin
sectioning, the blocks were stained in uranyl acetate and lead citrate 10
min each. Philips EM 208 Transmission Electron Microscope (Philips,
Eindhoven, Netherlands) connected with an AMT digital imaging system
(Advanced Microscopy Techniques Corp) was used to provide the highresolution digital imaging.
2.10. Western blot analysis
The proteins were extracted from MSC-Exo and tissues, respectively,
which were lysed in RIPA buffer (Invitrogen) containing the proteinase
inhibitor and homogenized. After centrifugation for 15 min at 12,000
rpm to remove cell debris, protein concentrations were determined
using a bicinchoninic acid assay (Thermo Fisher Scientific). 40 μg of
proteins were loaded then separated by 10% SDS-PAGE (Invitrogen) and
transferred to a nitrocellulose membrane using the iBlot transfer system
(Invitrogen). The membrane was probed with an appropriate primary
antibody and a secondary antibody conjugated to horseradish peroxi
dase. The antibodies against CD63 (ab134045, Abcam) and Alix
(mAb2171, Cell Signaling) were employed for the markers of exosomes;

3.2. Exosomes derived from MSCs attenuate functional deficits in the EAE
model
After induction of EAE by MOG35-55, a total 34 mice had disease onset
by day 10p.i.. Treatments with MSC-Exo, Exo-con or PBS control were
4
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Fig. 1. A. qNano shows distribution of MSC-Exo
particle size. B. TEM image of MSC-Exo. C.
Western blot analysis shows the exosomal pro
teins CD63 and Alix in MSC-Exo. D. MSCs trans
fected with CD63-GFP (green). E. Orthogonal
view of a confocal Z-stack image shows that Exo/
CD63-GFP (green) were internalized by neural
cells in the corpus callosum after IV injection. F.
Double immunostaining show that Exo/CD63GFP (green) colocalized to PDGFRa+ OPCs
(red), Scale bar in E = 10 μm, F = 25 μm. (For
interpretation of the references to colour in this
figure legend, the reader is referred to the web
version of this article.)

initiated on the EAE onset day (10p.i.). The MSC-Exo dose was chosen
based on our previous studies in animal models of CNS disorders (Moore
et al., 2019; Williams et al., 2019; Xin et al., 2013a; Zhang et al., 2015c;
Zhang et al., 2017a; Zhang et al., 2020). We have performed experi
ments to evaluate treatment dose, frequency and treatment window in
the EAE model in our pre-experimental study. Since the focus of the
current study is on the effects of MSC-Exo on remyelination, we delayed
treatment window to the onset day of EAE. The lower treatment doses (1

× 10^9 or 1 × 10^10 particles/injection) or treatment frequency (once a
week) did not improved functional recovery in this delayed treatment
strategy compared with the controls (data not shown). A treatment dose
(5 × 10^10 particles/injection) with the delayed treatment window (day
10p.i.) and treatment frequency (twice a week) was selected.
The treatments were randomly assigned and functional test score
(0–5) was measured daily up to 35 days after EAE induction (Fig. 2A).
The daily average clinical scores represent neurological functional

Fig. 2. A. The schema of treatments in the EAE model. B.
Average clinical daily score show that neurological
function significantly improved in the MOG-EAE mice
treated with MSC-Exo compared with the Exo-con and the
PBS control groups. Green arrows indicate the treatment
time points. *p < 0.05 vs MSC-Exo group. C. The schema
of experiments in the CPZ model. D. Social behavior test
in the CPZ mice treated with MSC-Exo and control. The
duration of time spent with empty column and stranger 1
(Session I), *p < 0.05, **p < 0.01 vs Empty, the duration
of time spent with stranger 1 and stranger 2 (Session II),
*p < 0.05 vs Stranger 1. N = 10 per group. (For inter
pretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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PBS control group), we employed the PBS group alone as the control
group to further analyze and investigate the mechanisms underlying the
functional benefits of MSC-Exo.

deficits; the higher score, the worse the functional outcome. Data show
that there is no significant difference of average clinical score in the Exocon group compared with the PBS group; however, MSC-Exo treatment
significantly decreased average clinical scores from day 14 to 35p.i.
compared to the Exo-con and PBS control treatments (p < 0.05)
(Fig. 2B), implying significant consistent therapeutic effect of MSC-Exo
treatment of the MOG-EAE model from day 14p.i. onward.
Since there is no significant difference of neurological functional
outcome between the two control groups (the Exo-control group and the

3.3. Exosomes derived from MSCs improve cognitive function in the CPZ
model
It is well known that demyelination affects cognitive function (Fan
et al., 2017). Five weeks of CPZ diet induce severe demyelination in this

Fig. 3. A. Western blot results show that the protein level of MBP significantly increased in the spinal cord of the MSC-Exo group compared with the control group. B
~ C. Representative images of immunofluorescent stainings of BrdU-NG2 (arrow) and BrdU-APC (arrow), respectively. Quantitative data show that proliferation of
OPCs (BrdU-NG2), differentiation of OPCs (BrdU-APC) and the number of APC+ cells significantly increased in the spinal cord of the MSC-Exo group compared with
the control group. D. Immunostaining data show that APP+ density significantly decreased in the spinal cord after MSC-Exo treatment compared with PBS treatment.
E. MBP immunostaining in the dorsal column of spinal cords. F. Enlarged area of red square in E by Paragon staining. G. Enlarged area of red square in F scanned by
TEM. TEM images show significant demyelination and axonal damage in the spinal cord of the control mice, and more intact axons with thinner myelin (arrows) in
the MSC-Exo group at day 35p.i. *p < 0.05 vs control. Scale bar =25 μm in B and C, 50 μm D, 25 μm in F, and 2 μm in G. (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
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experimental design (Zhang et al., 2019a). Here, we tested cognitive
functional outcome using the Social behavior test, which evaluates the
social interaction and social novelty of mice (Moy et al., 2004) (Fig. 2C).
Normal mice usually spend more time with another mouse, and even
more time to a novel intruder (stranger mouse) than a familiar one. In
Session one (the social interaction), mice spend more time with stranger
1 than with an empty cup in both the control group and MSC-Exo group.
In Session II (the social novelty test), there was no significant difference
in time spend with either stranger 1 and 2 in the control group; however,
the mice with MSC-Exo treatment spend significantly more time with the
stranger 2 vs stranger 1 (Fig. 2D). These data indicate MSC-Exo treat
ment improves cognitive function outcome after demyelination damage
in the CPZ model compared with the control group.
3.4. Exosomes derived from MSCs increase OPC differentiation and
remyelination in the EAE and CPZ demyelination models
Myelin plays an important role in supporting and protecting axons
and maintaining normal neurological function. Since MSC-Exo treat
ment promotes functional recovery after demyelination in the EAE and
CPZ models, we further investigated the profiles of myelination after the
MSC-Exo treatment.
MBP antibody was used to identify myelin content in the CNS. In the
EAE model, by measuring MBP protein level using Western blot analysis
we found that MSC-Exo treatment significantly increased myelination in
the spinal cord compared with the controls (p < 0.05) (Fig. 3A). We then
tested the hypothesis that increase of myelination may derive from
differentiation of OPCs. BrdU is a thymidine analog that is incorporated
into the DNA of dividing cells during S-phase, and is widely used for
mitotic labeling. Combined with OPC and OL markers, we can identify
not only OPC proliferation, but also OPC differentiation, since mature
OLs do not proliferate (Franklin and Ffrench-Constant, 2017; McTigue
and Tripathi, 2008). Spontaneous OPC proliferation and differentiation
was evident in the white matter of the spinal cord of the control EAE
mice at day 35p.i., identified by double immunofluorescent staining
BrdU-NG2 (OPC proliferation) and BrdU-APC (OPC differentiation),
respectively; MSC-Exo treatment further significantly increased the
number of BrdU+-NG2+ cells and BrdU+-APC+ cells which contribute to
increase the total number of mature OLs (APC+ cells) compared with the
controls (p < 0.05) (Fig. 3B, C). APP accumulation in the CNS has been
extensively used to evaluate axonal damage (Benjamini et al., 2021; Yu
et al., 2019). MSC-Exo treatment significantly decreased the APP+
density in the spinal cord at day 35p.i. compared with the PBS controls
(p < 0.05) (Fig. 3D). In addition, we further investigated remyelination
in the dorsal column of spinal cord by TEM. The dorsal column of the
spinal cord was identified by immunostaining with an antibody against
MBP (Fig. 3E), and then by staining with Paragon (Fig. 3F), shows sig
nificant demyelination. TEM images show substantial demyelination
and axonal damage present in the dorsal column of spinal cord of the
control group, whereas there were large areas of intact axons present in
mice treated with MSC-Exo and these intact axons exhibited thin myelin
suggesting the presence of remyelination (Fig. 3G). These data provide
evidence that MSC-Exo treatment enhances remyelination and reduces
axonal damage in the CNS of the EAE model.
The CPZ demyelination model was employed to further confirm our
findings in the EAE model. Two weeks of treatments were performed
after withdrawal of the CPZ diet. Significant increases of MBP immu
noreactive density evaluated by immunostaining (Fig. 4A) and protein
level of MBP measured by Western blot (Fig. 4B) were present in the
demyelinating corpus callosum of the MSC-Exo group compared with
the control group, indicating that MSC-Exo treatment promotes
remyelination compared with the control group. Moreover, using the
BrdU tracing method, we found that not only the numbers of APC+
mature OLs, but also the numbers of BrdU+-APC+ cells which represent
OPC differentiation significantly increased in the MSC-Exo group
compared with the control (Fig. 4C). These data further confirm our

Fig. 4. A. Immunostaining results show MBP+ density (myelin area); B.
Western blot results of MBP protein level; C. Double immunostaining of mature
OLs (APC, red) and proliferating cells (BrdU, green) in the corpus callosum.
MSC-Exo treatment significantly increased level of MBP, numbers of APC+ OLs
and BrdU+-APC+ (OPC differentiation, arrow) compared with the control group
after 2 weeks of treatments. *p < 0.05 vs control. Scale bar in A and C = 25um.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)

findings in the EAE model that MSC-Exo treatment increases OPC dif
ferentiation into mature OLs, enhances remyelination and improves
functional recovery in the EAE and CPZ demyelination models.
3.5. Exosomes derived from MSCs increase polarization of microglia in
the EAE and CPZ demyelination models
In addition to OL lineage cells, we investigated the effects of MSCExo on microglial function and neuroinflammation. In the EAE model,
the protein level of IBA1 (a marker of microglia) in the spinal cord was
not significantly different between the control and MSC-Exo groups;
however, the protein levels of YM1 (a marker of M2 phenotype of
microglia) was significantly increased, while the protein levels of iNOS
(a marker of M1 phenotype of microglia) was significantly decreased in
the MSC-Exo group compared with the controls, as measured by Western
blot (Fig. 5A). These data indicate that although MSC-Exo treatment did
not change the total amount of microglia, treatment increases the po
larization of M2 phenotype microglia which may contribute to the
myelin repair process. Moreover, the protein levels of pro-inflammatory
cytokines related to the M1 phenotype (IL-1β, TNFα and iNOS) were
significantly decreased, while the protein levels of anti-inflammatory
cytokines related to the M2 phenotype (IL-10 and TGFβ) were signifi
cantly increased in the MSC-Exo group compared with the controls
(Fig. 5B).
In the CPZ model, we found that there was no significant difference
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Fig. 5. A. Western blot results show that there was no significant difference of IBA1 protein level in the EAE model between the MSC-Exo group and the control
group, while YM1 protein level significantly increased and iNOS protein level significantly decreased in the spinal cord of the MSC-Exo group compared with the
control group. B. Analysis of Western blots show the protein levels of pro- and anti-inflammatory cytokines in the spinal cord of EAE mice treated with MSC-Exo and
PBS control on day 35p.i.. C. Immunostaining results show that there was no significant difference of the number of IBA1+ cells, while the number of YM1+ cells
significantly increased in the corpus callosum of CPZ mice treated with MSC-Exo compared with that in the control group. Scale bar = 25 μm. D. Western blot results
show that compared with the control, MSC-Exo did not significantly change IBA1 protein level, however, it significantly increased YM1 protein level and decreased
iNOS protein level in the corpus callosum on Week 7. E. Analysis of Western blots show the protein levels of pro- and anti-inflammatory cytokines in the corpus
callosum of CPZ mice treated with MSC-Exo and PBS on Week 7. *p < 0.05, **p < 0.01 vs control. N = 6 per group.

of cell number of IBA1+ microglia measured by immunostaining anal
ysis (Fig. 5C), or protein level of IBA1 measured by Western blot analysis
(Fig. 5D) in the corpus callosum between MSC-Exo and control groups;
however, the number of YM1+ cells and the protein level of YM1
significantly increased, while the protein level of iNOS significantly
decreased in the MSC-Exo group compared with the control (Fig. 5C, D).
The protein levels of the M1 phenotype related cytokine (IL-1β and
TNFα) were significantly decreased, while the protein levels of the M2
phenotype related cytokine (TGFβ) were significantly increased in the
MSC-Exo group compared with the controls (Fig. 5E). The data obtained
from the CPZ model support our findings from the EAE model, implying
that MSC-Exo treatment increases polarization of M2 phenotype of
microglia which may contribute to remyelination (Miron et al., 2013).

showed that MSC-Exo considerably reduced protein levels of TLR2,
IRAK1, and the TLR2 downstream target pNF-κB at day 35p.i. compared

3.6. Exosomes derived from MSCs inhibit the TLR2 signaling pathway in
the demyelination models
Fig. 6. A. Analysis of Western blots show the protein levels of TLR2, IRAK1 and
pNF-kB significantly decreased in the spinal cord of the EAE mice treated with
MSC-Exo compared with the PBS controls at day 35 p.i. B. Western blot data
show that MSC-Exo significantly decreased protein level of TLR2 and pNF-kB in
the corpus callosum at Week 7 compared with the controls (*p < 0.05).

We investigated the TLR2 signaling pathway which inhibits OPC
differentiation and remyelination (Back et al., 2005; Liu et al., 2017;
Santra et al., 2014; Sloane et al., 2010; Zhang et al., 2017b), and pro
motes neuroinflammation. Western blot analysis of spinal cord tissues
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to the control group (Fig. 6A).
In the CPZ model, MSC-Exo treatment also significantly decreased
protein levels of TLR2 and pNF-κB in the corpus callosum at week 7
compared to the control group (Fig. 6B). These data suggest that inhi
bition of the TLR2 signaling pathway by MSC-Exo and the ensuring
decrease in neuroinflammation contribute to the therapeutic effects of
MSC-Exo treatment of EAE and CPZ demyelination models.

conditions. Under disease conditions in the CNS, for example, MS,
microglia rapidly activate (M1 phenotype) and secrete proinflammatory cytokines and chemokines which result in demyelin
ation (Kremer et al., 2019; Lombardi et al., 2019). Microglia can also
shift to the anti-inflammatory phenotype (M2 phonotype) which secrete
restorative cytokines, chemokines and growth factors to facilitate neu
roregeneration, including promoting OPC differentiation and remyeli
nation (Lloyd et al., 2019; Miron et al., 2013). In the current study, MSCExo treatment was initiated on day 10p.i. (EAE model) and on the day of
CPZ diet withdrawal (CPZ model), when demyelination and functional
deficits occurred (Zhang et al., 2017b; Zhang et al., 2019a). There were
no significant differences of the protein level of IBA1 or the total cell
number of IBA+ microglia between the two treatment groups; however,
the polarization of M1/M2 phenotype was significantly changed be
tween MSC-Exo and control groups in the both demyelination models,
represented by MSC-Exo induced decrease of protein levels of iNOS and
M1 cytokines (IL-1β and TNFα) and increase of protein levels of YM1 and
M2 cytokines (IL-10 and TGFβ) (Jayasingam et al., 2019). These results
imply that the polarization of pro-inflammatory to anti-inflammatory
phenotype of microglia reduce neuroinflammation may contribute to
remeylination mediated by MSC-Exo.
Remyelination is limited by intrinsic and extrinsic inhibitors (Zhang
et al., 2015a; Zhang et al., 2016; Zhang et al., 2019a), and to-date there
are no clinically approved remyelination treatments (Lloyd et al., 2019).
Among the most prominent of remyelination obstacles, is the toll-like
receptor 2 (TLR2) signaling pathway (Jia et al., 2016; Liu et al., 2017;
Santra et al., 2014; Sloane et al., 2010; Wang et al., 2014; Zhang et al.,
2012). Toll-like receptors (TLRs) are a group of receptors widely
distributed in CNS, and TLR2 is a pattern-recognition receptor that
controls the innate immune responses in the initiation disease and reg
ulates CNS damage by modulating cytokine and chemokine secretion
(Fiebich et al., 2018; Gooshe et al., 2014). IRAK1 and NF-kB are the key
components amplifying responses in TLR2 signaling pathways (Liu
et al., 2017; Santra et al., 2014; Zhang et al., 2017b). Exosomes pass the
BBB, communicate with the parenchymal cells in the CNS, and deliver
biomaterials to recipient cells, including OPCs and microglia (Fig. 7). In
addition to its role in the control of immune responses, TLR2 is involved
in neuroregeneration (Fiebich et al., 2018). We and others have
demonstrated that the TLR2 signaling pathway directly inhibits OPC
differentiation and remyelination in vivo and in vitro (Back et al., 2005;
Hanafy and Sloane, 2011; Kremer et al., 2011; Kremer et al., 2013;
Santra et al., 2014; Sloane et al., 2010), indicating that the TLR2/
IRAK1/NF-kB pathway is a potential target for remyelination therapies.
We have demonstrated that negative regulation of the TLR2 signaling
pathway promotes OPC differentiation and remyelination in animal
models of EAE, CPZ, stroke and in in vitro cell cultures (Liu et al., 2017;
Santra et al., 2014; Zhang et al., 2016; Zhang et al., 2019a; Zhang et al.,
2012).
In addition to OPCs, MSC-Exo inactivate the TLR2 signaling pathway
in microglia, and switch from microglia from M1 to the M2 phenotype

4. Discussion
In this study, we demonstrated that treatment of EAE and CPZ animal
models of demyelination with cell-free exosomes derived from MSCs
ameliorates functional deficits via enhancement of OPC differentiation,
remyelination, modulation of polarization of microglia and reduction of
inflammatory response in the CNS.
We have demonstrated that MSCs have therapeutic benefits in the
animal models of CNS disease and injury, including stroke, trauma and
MS, when MSCs were transplanted by allograft, as well as xenograft
(Zhang et al., 2005). Based on our MSC studies of brain injury in nonhuman primates (Go et al., 2019; Go et al., 2020; Moore et al., 2019),
here, we tested whether administration of MSC-Exo derived from rhesus
monkey MSCs to mouse models of demyelination provides therapeutic
benefit. Due to the similarity to humans, nonhuman primates, e.g. rhe
sus monkey are used frequently in biomedical research (Phillips et al.,
2014).
Two complementary demyelination animal models (EAE and CPZ)
with the different inflammation levels in the CNS were employed in the
present study. In order to mimic clinical treatment, MSC-Exo were sys
temically administered to the animals and treatment windows were post
insults to the CNS, i.e. 10 days after MOG35-55 immunization (onset day
of EAE) or 5 weeks of CPZ diet (time of severe demyelination). We found
that MSC-Exo can pass the BBB as early as 4 h after IV administration,
and are internalized by parenchymal cells in the CNS, data which are
consistent with our and other studies of exosomes (Barteneva et al.,
2013; Chopp and Zhang, 2015; Pant et al., 2012; Raposo and Stoorvogel,
2013; Zhang and Chopp, 2016). Using a standard EAE scoring system on
a 0–5 disease severity scale and a Social behavior test, we found that
MSC-Exo significantly improved neurological function and cognitive
function in the EAE model and CPZ model, respectively. Furthermore,
morphological analysis and Western blot analysis were employed to
evaluate the changes in the CNS with the focus on OPCs and microglia.
OLs play an important role in maintenance of CNS function via
supporting the health and function of axons. OLs are vulnerable to CNS
insults, and damaged OLs have limited capability to self-repair and form
new myelin sheaths (McTigue and Tripathi, 2008) which leads to
demyelination and neurological and cognitive functional deficits. After
we confirmed that the MSC-Exo significantly improved neurological and
cognitive function in the EAE and CPZ models compared with the con
trols, we further investigated the changes of OPCs, OLs and myelin in
these demyelination animal models. The data revealed that: 1) myeli
nation in the white matter of spinal cord (EAE model) and the corpus
callosum (CPZ model) significantly increased in the MSC-Exo group
compared with the control group; 2) MSC-Exo treatment not only
increased OPC proliferation (BrdU+-NG2+), but also OPC differentiation
(BrdU+-APC+ cells); 3) TEM images show increased remyelination and
intact axons present in the white matter of spinal cords of the EAE model
in the MSC-Exo group. These data provide evidence that enhancement of
remyelination in the demyelinating CNS and the increased numbers of
intact axons resulting from MSC-Exo treatment, likely contribute to the
recovery of motor and cognitive functions.
In addition to OPCs, the effect of MSC-Exo on neuroinflammation
was investigated. Microglia play an important role in mediating myelin/
OL damage and myelin repair (Adams and Gallo, 2018; Butovsky and
Weiner, 2018; Kremer et al., 2019; Lombardi et al., 2019; Miron et al.,
2013; Wendeln et al., 2018). As the residential innate immune cells in
the CNS, microglia provide surveillance of the CNS under normal

Fig. 7. The sketch of the potential mechanisms of MSC-Exo actions.
9

J. Zhang et al.

Experimental Neurology 347 (2022) 113895

by inhibiting of neuroinflammation, and thereby promotes OPC differ
entiation into myelinating OLs. Here, we found that the activation of the
TLR2/IRAK1/NF-kB pathway decreased in the EAE and CPZ demyelin
ation models after MSC-Exo treatment, supporting this pathway as a
mechanism underlying the action of MSC-Exo on remyelination and
neuroinflammation.
MiRNAs are a class of small non-coding RNAs which act as important
regulators in the development, as well as in disease progression and
repair (Kosik, 2006). MiRNAs within MSC-Exo contribute to the thera
peutic effects of MSC-Exo on the CNS (Asgarpour et al., 2020; Ferguson
et al., 2018; Zhang et al., 2017c). From the top 23 miRNAs enriched in
MSC exosomes identified by Ferguson's group, let-7a, miR-23a and miR125b decrease activity of the TLR/IRAK1/NF-kB signaling pathway (Fan
et al., 2020), and miR-199 reduces NF-kB expression (Ferguson et al.,
2018). Further studies are warranted to analyze the molecular cargo of
the MSC-Exo, e.g. the miRNA and proteins which may mediate the ef
fects of MSC-Exo on remyelination and immunomodulation via inter
nalization by the recipient cells; and to investigate whether MSC-Exo
engineered to be enriched with desired elevated miRNAs enhance the
benefits of MSC-Exo.
Collectively, our findings indicate that MSC-Exo treatment promotes
remyelination by both directly acting on OPCs and indirectly acting on
microglia by releasing contraints on remyelination via inhibition of the
TLR2/IRAK1/NF-kB signaling pathway in the demyelinating CNS.
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5. Conclusions
Collectively, MSC-exosomes promote remyelination by directly
acting on OPCs and indirectly, by acting on microglia in the demyelin
ating CNS. This study provides the cellular and molecular bases for the
potential application of this cell-free exosomes for the treatment of CNS
demyelinating disease and injury.
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